key: cord-0854928-sg9bz372
authors: Derksen, Jeroen W G; May, Anne M; van de Poll-Franse, Lonneke V; de Rooij, Belle H; Hafkenscheid, Dorothee A; Verkooijen, Helena M; Koopman, Miriam; Vink, Geraldine R
title: Colorectal Cancer Care and Patient’s Perceptions Before and During COVID-19: Implications for Subsequent SARS-CoV-2 Infection Waves
date: 2021-05-13
journal: JNCI Cancer Spectr
DOI: 10.1093/jncics/pkab047
sha: 1512cbf08fafc2d2dc742f4928274385a0a4f2c1
doc_id: 854928
cord_uid: sg9bz372

BACKGROUND: Changes in colorectal cancer (CRC) care planning due to the coronavirus disease 2019 (COVID-19) pandemic and associated health-related quality of life (HRQoL) and well-being of patients with CRC are unknown. We report changes in CRC care and patient-reported outcomes (PROs) including HRQoL, distress, and loneliness during the first wave of SARS-CoV-2. METHODS: In April 2020, 4,984 patients included in the nationwide Prospective Dutch Colorectal Cancer cohort were invited to complete a COVID-19-specific questionnaire, together with the validated EORTC QLQ-C30, De Jong Gierveld, and HADS. Clinical data were obtained from the Netherlands Cancer Registry. Scores were compared with the year prior to COVID-19, and with an age- and sex-matched control population during COVID-19. RESULTS: In total, 3,247 (65.1%) patients responded between April and June 2020. Seventeen percent of patients had cancelled/postponed/changed hospital visits into a telephone- or video consult while 5.3% had adjusted/postponed/cancelled treatment. Compared to controls, patients reported worse HRQoL, but comparable distress and less social loneliness (patients = 21.2%; controls = 32.9%). Compared to pre-COVID-19, clinically meaningful deterioration of HRQoL was more prevalent in patients with changes in cancer care planning than in patients without changes. Prior to undergoing or currently undergoing treatment, and infection worries were associated with lower HRQoL. CONCLUSIONS: CRC patients reported equal anxiety and depression, but worse HRQoL than the control population. Changes in care planning were associated with deterioration of HRQoL and increased anxiety. In case of one or more risk factors, healthcare specialists should discuss (mental) health status and possible support during future SARS-CoV-2 infection waves or comparable pandemics.

The current study is an observational study embedded in the ongoing nationwide Prospective Dutch Colorectal Cancer (PLCRC) cohort; an initiative coordinated by the Dutch Colorectal Cancer Group. PLCRC consists of patients diagnosed with a malignancy of the colon and/or rectum in the Netherlands. The PLCRC study protocol, described in more detail elsewhere 2 , has been approved by the Medical Research Ethics Committee (MREC) Utrecht, the Netherlands. At PLCRC entry, participants provide informed consent and can opt to receive longitudinal questionnaires, which allows for a swift implementation of questionnaire-based observational studies. Clinical data was obtained through linkage with the Netherlands Cancer Registry (NCR).

In total, 4,984 PLCRC participants who provided informed consent for receiving questionnaires were invited to participate in the current study and received an additional COVID-19-specific questionnaire on oncologic practice patterns, cancer care, HRQoL and well-being during the COVID-19 outbreak. During the first national lockdown from March 23 until June 1, 2020, the COVID-19-specific questionnaire was sent out on April 17, 2020 and was received until June 1, 2020. Patients were included in the longitudinal analysis when a previous questionnaire of PLCRC was completed in the year before the COVID-19 pandemic, i.e. between January 1, 2019 and January 31, 2020.

Normative data on quality of life, symptoms, functioning and comorbidities from a representative sample of the Dutch population was available from the PROFILES registry, and collected between May 4-26, 2020 3 . This non-cancer control population was matched to the PLCRC population based on a frequency distribution over age (<30, 30-49, 50-69, ≥70) and sex strata to maximize the number of control participants matched to patients (ratio patients to norm 1:0.4).

Sociodemographic and clinical data were obtained from the NCR and include age, sex, date of primary cancer diagnosis, tumor location, stage at diagnosis, primary treatment received, and time since diagnosis (categorized). International Classification of Diseases (ICD)-10 was used to classify tumor types, and TNM was used to classify disease stage 4, 5 . Additional patient-reported sociodemographic data included educational level, marital status/partnership, living situation, height and weight. Patient-reported clinical variables included current presence of metastases, current treatment status, and presence of comorbidities (adapted Self-administered Comorbidity Questionnaire 6 ). Detailed information on data categorization and design of questionnaires can be found in the Supplementary Methods.

regarding SARS-CoV-2 infection status, the fear of getting COVID-19, and the impact on cancer treatment and follow-up care as experienced by the patient were developed by the Dutch Federation of Cancer Patients Organisations (NFK) and the PROFILES Registry Group. Experiences with TC/VCs were assessed based on questions developed by Barsom et al. 7 , while the EORTC QLQ-C30 response format was applied.

QLQ-C30 8 was used to evaluate the patients' quality of life, daily functioning, and complaints of common symptoms. Only during COVID-19, an additional single-item scale was added to assess worries about future health (from EORTC library 9 ). Linear transformation was used to obtain scores ranging from 0 to 100, where a higher score represents a higher ('better') level of functioning or a higher ('worse') level of symptoms 10 .

symptoms of patients were assessed using the Hospital Anxiety and Depression Scale (HADS) 11 . To identify a clinically relevant level of anxiety or depression, a cut-off score of 8 was used 12 .

using the De Jong Gierveld short scales for social and emotional loneliness 13 .

Patient characteristics were compared with the matched non-cancer control population by means of the independent samples t-test or Chi-square test. To facilitate the interpretation of cross-sectional HRQoL measures, prevalences of patients and control participants exceeding thresholds for clinical importance (TCIs) were compared 14 . General Linear Models, logistic-and ordinal regression models were used to compare well-being of CRC patients with the matched control population, while adjusting for education level, marital status, living situation, comorbidities, and COVID-19 status. Mean changes in HRQoL, anxiety and depression from <1 year pre-to during the COVID-19 pandemic were analyzed using the paired samples t-test. In the subgroup of patients in treatment, a sensitivity analysis was performed by metastatic vs. non-metastatic disease. Logistic regression was used to test differences in prevalence of patients reporting a clinically meaningful worsening of HRQoL (i.e. ≥10 points 15 ), anxiety, and depression (i.e. ≥1.5 points 16 ) by alterations in cancer care planning, while adjusting for age, sex, and comorbidities. Here, the Holm's sequential Bonferroni procedure was used to deal with inflated familywise error rates due to multiplicity 17 . Lastly, multivariable linear regression models including a-priori selected variables were used to determine factors associated with changes in global quality of life, anxiety, and depression from pre-to during the COVID-19 outbreak. A P value of less than .05 was considered statistically significant unless otherwise stated and all tests were 2-sided.

A total of 3,247 patients (65.1%) returned their COVID-19-specific questionnaire (Figure 1) . A total of 2,664 non-cancer control participants (75.9%) completed the COVID-19-specific questionnaire, of whom 1,114 were age-and sexmatched to the patients.

Participants had a mean age of 67 (SD=10) years, 63.1% were male, and 19.7% of the patients reported presence of metastases (Tables 1 and 2). Patients reported more comorbidities, were higher educated, more often married, and more often lived with a partner without children, compared to the control population. Changes in hospital visits or treatment plan were associated with presence of comorbidities (respectively 37.0% and 41.5% with ≥2 comorbidities vs. 33.4% in the total CRC patient population).

In our total study population, seventeen percent of patients had cancelled and/or postponed hospital visits, or visits that were changed into a telephone consultation (TV) or video consultation (VC), and 5.3% reported adjusted, postponed, and/or cancelled treatment.

Of 594 patients prior to or currently in treatment during COVID-19, 86 patients (14.5%) reported postponed and/or cancelled hospital visits, and 128 patients (21.5%) had their visit changed to a TC/VC (Supplementary Table 1 ). In 34 patients (5.7%) treatment was adjusted, in 48 patients (8.1%) postponed, and in 4 patients (0.7%) systemic or targeted treatment was cancelled. In case of physical complaints or concerns, patients reported a barrier to contact their general practitioner (11.3%) or medical specialist/nurse (6.4%). These undesired hesitations were even more common in the non-cancer control population (respectively 37.9% and 31.3%). Table 1 ). In case of physical complaints or concerns, these patients reported they contact their general practitioner (18.9%) or medical specialist/nurse (14.0%) less quickly as compared to pre-COVID-19, while respectively 70.8% and 60.2% reported no difference as compared to pre-COVID-19.

For 379 patients (12.2%), a face-to-face visit was changed into a TC (n=365) or VC (n=14). Most patients reported this change to be very/quite suitable (66.6%), but 47.1% reported that their physical condition could not/poorly be assessed (Figure 2 ).

The majority (87.8%) was not worried about privacy issues, and although 44.9% would use a TC/VC again, a face-to-face consultation remained most preferred (70.4%), also in the subgroup of patients prior to or in treatment (80.7%).

Although on average, CRC patients did not exceed TCIs regarding HRQoL during the COVID-19 pandemic, a statistically significantly larger proportion of CRC patients reported levels of fatigue, sleep disturbance, and functional impairments that exceed TCIs, as compared to the non-cancer control population (Table 3) .

Elevated levels of anxiety and depression were equally present in CRC patients and controls (anxiety: respectively 11.3% vs. 10.2%, depression: respectively 11.4% vs.

12.3%), but patients reported statistically significantly less moderate-severe loneliness -especially in terms of social loneliness (respectively 21.2% vs. 32.9%).

Regarding concerns about getting SARS-CoV-2 infection, CRC patients were equally concerned as control participants.

Patients in follow-up ( Table 4 ) who reported to have had changed/postponed/cancelled hospital visits, compared to patients without changes in cancer care planning, more frequently reported a clinically meaningful decrease in role (respectively 20.8% vs. 16.4%), emotional (respectively 18.7% vs. 10.3%), and social functioning (respectively 15.1% vs. 11.1%), and more often an increase in fatigue (respectively 27.2% vs. 18.1%), sleep disturbance (respectively 17.7% vs.

12.1%), and anxiety (respectively 25.1% vs. 18.9%).

In patients in treatment ( Table 5) , clinically meaningful worsening of HRQoL, anxiety and depression was more prevalent compared to patients in follow-up. In those with adjusted/postponed/cancelled treatment, compared to patients without changes in cancer care planning, clinically meaningful deterioration occurred most for physical (respectively 29.0% vs. 23.4%), cognitive (respectively 30.4% vs. 23.7%), and social functioning (respectively 34.8% vs. 28.8%), as well as for anxiety (respectively 29.5% vs. 22.1%). Sensitivity analysis within this group showed no statistically significant differences in HRQoL, depression, and anxiety between patients with metastatic vs. non-metastatic disease in neither of the three settings of cancer care planning (data not shown).

Being prior to or in treatment during the COVID-19 pandemic, and being quite a bit/very worried about getting a SARS-CoV-2 infection were statistically significantly associated with a decrease in HRQoL (Supplementary Table 2 Although most patients reported this change to be very much/quite suitable, the vast majority favors a face-to-face consultation in the future. This pandemic has catalyzed the implementation of telemedicine to deliver healthcare, but remaining challenges both for patients and medical staff require continued research and development to ultimately find implementation in routine healthcare 18, 19 . Moreover, anticancer treatments were adjusted in 5.7%, postponed in 8.1%, and cancelled in 0.7% of the patients in treatment. During this early phase of the COVID-19 outbreak, a statistically significantly larger proportion of CRC patients reported levels of fatigue, sleep disturbance, and health-related functional impairments exceeding TCIs, compared to non-cancer controls. Mild/severe anxiety and depression were reported equally, while patients reported statistically significantly less social loneliness.

In patients in follow-up during the COVID-19 pandemic who had hospital visits cancelled/postponed/changed into TC/VC, the proportion of clinically meaningful worsening of role, emotional, and social functioning, fatigue, sleep disturbance and anxiety was statistically significantly higher compared to patients without changes in cancer care planning. Interestingly, in patients who were prior to or in treatment during the COVID-19 pandemic, the differences between patients with and without changes in treatment were non-statistically significant.

Nevertheless, in this group, the overall prevalence of clinically meaningfully deteriorated HRQoL and anxiety was higher compared to those in follow-up. Despite the absence of statistical significance, patients of whom treatment was adjusted/postponed/cancelled, reported more often a clinically meaningful increase in anxiety than patients without changes.

Other studies that investigated anxiety and depression in cancer patients during the COVID-19 outbreak, reported mild-severe anxiety levels in 36-56% of patients, and mild-severe depression levels in 19-47% of patients 20-23 . This difference with our population (11.3%) might be explained by differences in study population, cancer types, and nationality. In a Dutch study in breast cancer patients, comparable mean levels of anxiety and depression were observed that also did not statistically significantly change from pre-COVID-19 to during the COVID-19 pandemic 24 . Our results confirm previously reported data of two large Dutch cohort studies that A limitation of the current study was that some clinical information were selfreported by patients, which could have led to misclassification and therefore dilution of our results. Although expected to be of little influence 26 , results may be prone to seasonality, as questionnaires were completed during spring 2020 and compared to 2019 year-round. In contrast, PROs are highly valuable as a direct measure of how patients' health and well-being were perceived. Second, the small number of patients in treatment with changes in cancer care might have influenced the magnitude of statistical significance. Therefore, it is important to consider the direction and size of the observed effect sizes. Third, since we lack information on reasons to not participate in this study, an under-or overestimation of the results due to selective response could not be ruled out. Lastly, we observed baseline differences between CRC patients and the control population, which could influence comparisons between the two groups, however, models were adjusted for the imbalanced factors.

There are also several strengths related to this analysis, including the large number of respondents which allowed for comprehensive analyses in a specific patient population. Moreover, the benefit of implementing this questionnaire-based study in an ongoing cohort with clinical data and PROs from diagnosis onwards is that data before the COVID-19 outbreak was available allowing for a comparison with the year before. Additionally, this enables longitudinal modelling of repeated PROs during future SARS-CoV-2 infection waves and subsequent government-imposed national prevention measures. This will provide further insight in the impact of ongoing social distancing and other nationwide prevention measures on patients' well-being and will help tailor mental support strategies.

To conclude, between 9.8%-18.9% of patients without changes in cancer care during follow-up reported clinically meaningful worsening of HRQoL, anxiety and depression compared to the year before the COVID-19 outbreak, and in patients prior to or in treatment, these prevalences increased to 14.6%-34.9%. Both in patients in treatment and in follow-up, changes in cancer care planning were associated with increased deterioration of several aspects of HRQoL and anxiety.

Interestingly, during COVID-19, patients experienced statistically significantly less social loneliness than the non-cancer control population. To optimally meet patient needs, (mental) health status and possible support options should be discussedespecially in patients presenting with one or more risk factors -during future SARS-CoV-2 infection waves or comparable pandemics.

The current work was not supported by a specific funding source. We would like to thank all patients who participated in this study. 

Annebeth W

The Netherlands), Helgi H. Helgason (Department of Medical Oncology

Hingh (Department of Surgery, Catharina Hospital

The Netherlands), Anja U.G. van Lent (Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Hospital

Polée (Department of Medical Oncology

Patricia Quarles van Ufford-Mannesse

Arjan Schouten van der Velden (Department of Surgery

Lieke Simkens (Department of Medical Oncology

Sonneveld (Department of Surgery

Frederiek Terheggen (Department of Medical Oncology

Maarten Vermaas (Department of Surgery

Vles (Department of Surgery, Ikazia Hospital

The Netherlands), Aad I. de Vos (Department of Medical Oncology, Van Weel-Bethesda Hospital

Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period

The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts

TNM classification of malignant tumors

ICD-10 : international statistical classification of diseases and related health problems: tenth revision

The self-administered comorbidity questionnaire: A new method to assess comorbidity for clinical and health services research

Video consultation during follow up care: effect on quality of care and patient-and provider attitude in patients with colorectal cancer

The European-Organization-for-Research-and-Treatment-of-Cancer Qlq-C30 -a Quality-of-Life Instrument for Use in International Clinical-Trials in Oncology

The EORTC QLQ-C30 Scoring Manual

In: Published by: European Organisation for Research and Treatment of Cancer B, editor. 11. Zigmond AS, Snaith RP. The hospital anxiety and depression scale

The validity of the Hospital Anxiety and Depression Scale. An updated literature review

The De Jong Gierveld short scales for emotional and social loneliness: tested on data from 7 countries in the UN generations and gender surveys

Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research

Interpreting the significance of changes in health-related quality-of-life scores

The minimal important difference of the

A simple sequential rejective multiple test procedure

Implications of Telemedicine in Oncology during the COVID-19 Pandemic

≥10 point decrease in HRQoL functional scales or ≥10 point increase in symptoms scales, and ≥1.5 points increase in HADS scales. COVID-19 = Coronavirus disease

TC/VC = Telephone consultation/Video consultation

HRQoL = Health-related quality of life

-sided), adjusted for: age, sex, and number of comorbidities

≥10 point decrease in HRQoL functional scales or ≥10 point increase in symptoms scales, and ≥1.5 points increase in HADS scales. COVID-19 = Coronavirus disease

TC/VC = Telephone consultation/video consultation

HRQoL = Health-related quality of life

b P value for difference in prevalence of worsened HRQoL and HADS between groups, using logistic regression models (2-sided), adjusted for: age, sex, and number of comorbidities